These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

563 related items for PubMed ID: 26597311

  • 21. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women.
    Portman DJ, Labrie F, Archer DF, Bouchard C, Cusan L, Girard G, Ayotte N, Koltun W, Blouin F, Young D, Wade A, Martel C, Dubé R, other participating members of VVA Prasterone Group.
    Menopause; 2015 Dec; 22(12):1289-95. PubMed ID: 25968836
    [Abstract] [Full Text] [Related]

  • 22. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks.
    Martel C, Labrie F, Archer DF, Ke Y, Gonthier R, Simard JN, Lavoie L, Vaillancourt M, Montesino M, Balser J, Moyneur É, other participating members of the Prasterone Clinical Research Group.
    J Steroid Biochem Mol Biol; 2016 May; 159():142-53. PubMed ID: 26972555
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy.
    Archer DF.
    J Steroid Biochem Mol Biol; 2015 Jan; 145():139-43. PubMed ID: 25201455
    [Abstract] [Full Text] [Related]

  • 27. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women.
    Panay N, Palacios S, Bruyniks N, Particco M, Nappi RE, EVES Study investigators.
    Maturitas; 2019 Jun; 124():55-61. PubMed ID: 31097180
    [Abstract] [Full Text] [Related]

  • 28. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens.
    Labrie F, Martel C, Bérubé R, Côté I, Labrie C, Cusan L, Gomez JL.
    J Steroid Biochem Mol Biol; 2013 Nov; 138():359-67. PubMed ID: 23954500
    [Abstract] [Full Text] [Related]

  • 29. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia.
    Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J.
    Climacteric; 2011 Apr; 14(2):282-8. PubMed ID: 21244215
    [Abstract] [Full Text] [Related]

  • 30. Vulvovaginal atrophy of menopause and its impact on sexual function in an Italian clinical cohort of post-menopausal women.
    Nappi RE, Guida M, Marchesoni D, Cianci A, Pellegrino A, Remorgida V, Di Paolantonio T, Benedetti Panici P, investigators of the EVES Study.
    J Obstet Gynaecol; 2021 Feb; 41(2):290-297. PubMed ID: 33432869
    [Abstract] [Full Text] [Related]

  • 31. Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review.
    Portman DJ, Goldstein SR, Kagan R.
    Climacteric; 2019 Feb; 22(1):65-72. PubMed ID: 30554531
    [Abstract] [Full Text] [Related]

  • 32. An overview of dehydroepiandrosterone (EM-760) as a treatment option for genitourinary syndrome of menopause.
    Holton M, Thorne C, Goldstein AT.
    Expert Opin Pharmacother; 2020 Mar; 21(4):409-415. PubMed ID: 31928093
    [Abstract] [Full Text] [Related]

  • 33. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.
    Constantine GD, Simon JA, Pickar JH, Archer DF, Kushner H, Bernick B, Gasper G, Graham S, Mirkin S, REJOICE Study Group.
    Menopause; 2017 Apr; 24(4):409-416. PubMed ID: 27922936
    [Abstract] [Full Text] [Related]

  • 34. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
    Portman D, Palacios S, Nappi RE, Mueck AO.
    Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
    [Abstract] [Full Text] [Related]

  • 35. Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal Women.
    Constantine GD, Bouchard C, Pickar JH, Archer DF, Graham S, Bernick B, Mirkin S.
    J Womens Health (Larchmt); 2017 Jun; 26(6):616-623. PubMed ID: 28355090
    [Abstract] [Full Text] [Related]

  • 36. A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom.
    Kroll R, Archer DF, Lin Y, Sniukiene V, Liu JH.
    Menopause; 2018 Feb; 25(2):133-138. PubMed ID: 28926514
    [Abstract] [Full Text] [Related]

  • 37. Preliminary results of a single-arm pilot study to assess the safety and efficacy of visnadine, prenylflavonoids and bovine colostrum in postmenopausal sexually active women affected by vulvovaginal atrophy.
    Laganà AS, Vitale SG, Stojanovska L, Lambrinoudaki I, Apostolopoulos V, Chiofalo B, Rizzo L, Basile F.
    Maturitas; 2018 Mar; 109():78-80. PubMed ID: 29452786
    [Abstract] [Full Text] [Related]

  • 38. Effects of preoperative intravaginal estrogen on pelvic floor disorder symptoms in postmenopausal women with pelvic organ prolapse.
    Rahn DD, Richter HE, Sung VW, Hynan LS, Pruszynski JE.
    Am J Obstet Gynecol; 2023 Sep; 229(3):309.e1-309.e10. PubMed ID: 37244454
    [Abstract] [Full Text] [Related]

  • 39. Efficacy of intravaginal dehydroepiandrosterone (DHEA) for symptomatic women in the peri- or postmenopausal phase.
    Sauer U, Talaulikar V, Davies MC.
    Maturitas; 2018 Oct; 116():79-82. PubMed ID: 30244783
    [Abstract] [Full Text] [Related]

  • 40. A medical device containing purified bovine colostrum (Monurelle Biogel) in the treatment of vulvovaginal atrophy in postmenopausal women: Retrospective analysis of urinary symptoms, sexual function, and quality of life.
    Schiavi MC, Di Tucci C, Colagiovanni V, Faiano P, Giannini A, D'Oria O, Prata G, Perniola G, Monti M, Zullo MA, Muzii L, Benedetti Panici P.
    Low Urin Tract Symptoms; 2019 Apr; 11(2):O11-O15. PubMed ID: 29057583
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.